MEDIXALL GROUP, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -.--% |
|
-.--% | -.--% |
| 2023 | MediXall Group, Inc. Announces CFO Changes | CI |
| 2023 | MediXall Group, Inc. Appoints Scott S. Powell as Member of Its Board of Directors | CI |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 132.9 | 149.5 | 151.4 | 88.79 | 113.7 | 77.59 |
| Enterprise Value (EV) 1 | 132.7 | 149.3 | 151.1 | 88.36 | 114 | 80.41 |
| P/E ratio | -75.2 x | -49 x | -47.3 x | -14 x | -17 x | -10.5 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 5,979 x | 80,455 x | 56,394 x | - | 7,583 x | 1,309 x |
| EV / Revenue | 5,971 x | 80,347 x | 56,271 x | - | 7,599 x | 1,357 x |
| EV / EBITDA | -81 x | -51.6 x | -44.2 x | -14.9 x | -17.9 x | -12.8 x |
| EV / FCF | -81.4 x | -105 x | -136 x | -44.3 x | -49.3 x | -70.4 x |
| FCF Yield | -1.23% | -0.95% | -0.73% | -2.26% | -2.03% | -1.42% |
| Price to Book | -606 x | 289 x | 407 x | 239 x | -338 x | -21.3 x |
| Nbr of stocks (in thousands) | 57,796 | 66,438 | 75,709 | 96,511 | 108,286 | 121,233 |
| Reference price 2 | 2.300 | 2.250 | 2.000 | 0.9200 | 1.050 | 0.6400 |
| Announcement Date | 3/1/18 | 5/16/19 | 5/14/20 | 6/17/21 | 4/19/22 | 8/9/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.0222 | 0.001858 | 0.002685 | - | 0.015 | 0.0593 |
| EBITDA 1 | -1.638 | -2.894 | -3.417 | -5.928 | -6.362 | -6.285 |
| EBIT 1 | -1.641 | -2.897 | -3.421 | -5.932 | -6.366 | -6.321 |
| Operating Margin | -7,380.62% | -155,907.37% | -127,409.72% | - | -42,456.11% | -10,665.08% |
| Earnings before Tax (EBT) 1 | -1.641 | -2.983 | -3.421 | -5.932 | -6.201 | -6.83 |
| Net income 1 | -1.641 | -2.983 | -3.421 | -5.932 | -6.201 | -6.83 |
| Net margin | -7,380.62% | -160,572.07% | -127,409.72% | - | -41,350.94% | -11,524.63% |
| EPS 2 | -0.0306 | -0.0459 | -0.0423 | -0.0659 | -0.0619 | -0.0612 |
| Free Cash Flow 1 | -1.63 | -1.421 | -1.109 | -1.993 | -2.309 | -1.142 |
| FCF margin | -7,332.06% | -76,453.23% | -41,310.09% | - | -15,399.01% | -1,926.14% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/1/18 | 5/16/19 | 5/14/20 | 6/17/21 | 4/19/22 | 8/9/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 0.25 | 2.82 |
| Net Cash position 1 | 0.19 | 0.2 | 0.33 | 0.43 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.0396 x | -0.4483 x |
| Free Cash Flow 1 | -1.63 | -1.42 | -1.11 | -1.99 | -2.31 | -1.14 |
| ROE (net income / shareholders' equity) | 290% | -1,087% | -727% | -1,522% | -29,681% | 341% |
| ROA (Net income/ Total Assets) | -425% | -324% | -257% | -287% | -287% | -396% |
| Assets 1 | 0.3862 | 0.9202 | 1.333 | 2.065 | 2.162 | 1.723 |
| Book Value Per Share 2 | -0 | 0.0100 | 0 | 0 | -0 | -0.0300 |
| Cash Flow per Share 2 | 0 | 0 | 0.0100 | 0.0100 | 0 | 0 |
| Capex 1 | 0.02 | 0.01 | 0.01 | 0.01 | 0 | 0 |
| Capex / Sales | 69.41% | 392.47% | 390.99% | - | 5.6% | 2.33% |
| Announcement Date | 3/1/18 | 5/16/19 | 5/14/20 | 6/17/21 | 4/19/22 | 8/9/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 159 | |
| +7.84% | 218B | |
| +7.35% | 184B | |
| +13.04% | 135B | |
| +26.03% | 107B | |
| -1.33% | 62.38B | |
| +11.80% | 51.37B | |
| +4.81% | 50.9B | |
| +0.30% | 40.87B | |
| +2.78% | 36.28B |
- Stock Market
- Equities
- MDXL Stock
- Financials MediXall Group, Inc.
